Shanghai Celfuture Biotech Co., Ltd.
1 clinical trials · Sponsor
◉ Watch Shanghai Celfuture Biotech Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer (NCT05684211) | Shanghai Celfuture Biotech Co., Ltd. | 2023-01-01 |
Track Shanghai Celfuture Biotech Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.